GlobeNewswire

Server-Side Exploits Dominate Threat Landscape and OT Vulnerabilities Rise 120 Percent Says Skybox Security's Inaugural Vulnerability and Threat Trends Report

Dela

Analysis of 2017 threat landscape trends shows that assets most difficult to patch are increasingly vulnerable

 

SAN JOSE, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Skybox(TM) Security, a global leader in cybersecurity management, announced today the release of its inaugural Vulnerability and Threat Trends Report, which analyzes vulnerabilities, exploits and threats in play in 2017. The report, compiled by the team of research analysts at the Skybox Research Lab, aims to help organizations align their security strategy with the reality of the current threat landscape.

A trend observed for the last several years has seen threat actors turn cybercrime into a money-making machine. An integral part of this approach means taking the path of least resistance: leveraging existing attack tools rather than developing new ones, using the same attack on as many victims as possible and targeting "low-hanging fruit." Findings of the report shed light on how those "fruits" have changed to include the assets that are generally more difficult to patch.

During 2017, the vast majority of exploits affected server-side applications (76 percent), up 17 points since 2016. Skybox Security Chief Technology Officer Ron Davidson points out that dealing with server-side vulnerabilities is always more difficult because the higher-value assets require more consideration than simply if there is a patch available or not. "As more functions rely on servers than on clients," he explains, "organizations need to have the means to understand these server-side vulnerabilities in context - of the asset criticality, the surrounding topology and security controls, and the exploit activity in the wild. Only then can they accurately decide the optimal patching priority and schedule."

The increase in server-side exploits corresponds with the continued decline in the use of exploit kits relying on client-side vulnerabilities, which accounted for only a quarter of exploits in the wild that year. This is due in part to the demise of major exploit kit players like Angler, Neutrino and Nuclear, with no comparable frontrunner rising to replace them.

"This does not mean, however, exploit kits are gone," said Marina Kidron, senior security analyst and group leader of the Skybox Research Lab. "If there's one thing we know about cybercriminals, it's that they're constantly changing tactics, and so the next 'exploit kit giant' is very likely in development as we speak. We also suspect that some kits have 'gone private,' and are used exclusively by their developers in hopes of prolonging their viability."

Instances of newly-published sample exploit code have also increased, with the monthly average jumping 60 percent in 2017. With minimal adjustments - or none at all - attackers can turn these samples into fully functioning exploits for their own use. This scenario was the case with the NSA EternalBlue exploit leaked by The Shadow Brokers and used in the WannaCry and NotPetya attacks, among others. Such leaks are putting advanced attack tools in the hands of lower-skilled cyberattackers, enhancing the capabilities of an already well-outfitted threat landscape.

"Organizations need to stay up to speed with not only active exploits in the wild," said Kidron, "but also factor in vulnerabilities with available exploit code to their prioritization processes. While the latter set doesn't represent an imminent threat, they can make the jump to active exploitation very quickly - security teams need actionable intelligence at-the-ready when they do."

The report also shows that in 2017 there was a 120-percent increase in new vulnerabilities specific to operational technology (OT) compared to the previous year (OT includes monitoring and control devices common in critical infrastructure organizations such as energy producers, utilities and manufacturers, among others). This spike is particularly concerning as many organizations have poor or non-existent visibility of the OT network, especially when it comes to vulnerabilities as active scanning is generally prohibited.

"OT is too often in the dark, and that means security management isn't getting the full picture of cyber risk in their organization," said Kidron. "Even when patchable vulnerabilities are identified, OT engineers are understandably hesitant to install the update, as it could disrupt services, cause equipment damage or even risk life and limb. Organizations with OT networks need to have strategies in place not just for OT vulnerability assessment and patching prioritization, but also to unify such processes with those in the IT network to truly understand and manage risk."

Overall, new vulnerabilities catalogued by MITRE's National Vulnerability Database doubled in 2017. The jump was largely due to organizational improvements at MITRE and increased security research by vendors and third-parties, including vendor-sponsored bug bounty programs. The result is more than 14,000 newly assigned CVEs. Whatever the reason, it introduced yet more challenges to the teams responsible for managing vulnerabilities. "In 2017, if you were still relying on traditional prioritization methods like CVSS scores only, your laundry list just got longer," said Davidson. "In the year ahead, we may well see an even higher figure. Organizations have got to take a drastically different approach to vulnerability management."

Skybox recommends establishing a threat-centric vulnerability management (TCVM) program to adapt to these changes in the threat landscape and those yet to come. The TCVM approach helps security practitioners focus on the small subset of vulnerabilities most likely to be used in an attack by analyzing them from the interconnected perspectives of the business, network and threats in play.

To read the full report, click here. To learn more about Skybox TCVM, visit skyboxsecurity.com/tcvm.

About Skybox Research Lab 
The Skybox(TM) Research Lab is team of security analysts who daily scour data from dozens of security feeds and sources as well as investigate sites in the dark web. The Research Lab validates and enhances data through automated as well as manual analysis, with analysts adding their knowledge of attack trends, cyber events and TTPs of today's attackers. Their ongoing investigations determine which vulnerabilities are being exploited in the wild and used in distributed crimeware such as ransomware, malware, exploit kits and other attacks exploiting client- and server-side vulnerabilities.

For more information on the methodology behind the Skybox Research Lab and to keep up with the latest vulnerability and threat intelligence, visit www.vulnerabilitycenter.com.

About Skybox Security
Skybox provides the industry's broadest cybersecurity management platform, delivering comprehensive attack surface visibility. Skybox delivers the context needed to quickly identify and fix vulnerabilities and security weaknesses within large, complex networks - including physical, virtual, multi-cloud and OT environments.  The Skybox(TM) Security Suite integrates with more than 120 networking and security technologies to give insight on how to improve efficiency and effectiveness of vulnerability and threat management and firewall and security policy management. 

© 2018 Skybox Security, Inc. All rights reserved. Skybox Security and the Skybox Security logo are either registered trademarks or trademarks of Skybox Security, Inc., in the United States and/or other countries. All other trademarks are the property of their respective owners. Product specifications subject to change at any time without prior notice.

CONTACT INFORMATION

Skybox Security
Tawnya Lancaster
Director of Brand and Communications
408-205-1618 | Tawnya.lancaster@skyboxsecurity.com

OneChocolate for Skybox Security
North America: Brian Blank
1-415-606-8381 | brianb@onechocolatecomms.com

United Kingdom: Daniel Couzens
+44 (0)20 7437 0227 | DanielC@onechocolatecomms.co.uk

Germany: Melanie Grasser
+49 (0)89 3888 920 10 | MelanieG@onechocolatecomms.de

France: Xavier Delhôme
+33 1 41 31 75 09 | xavier@onechocolate.fr

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Skybox Security via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum